Alzex Neuropharma Inc. (TRRI)

Alzex Neuropharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007
Period Ending	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007
Operating Revenue	4.72	3.78	8.79	14.97	15.13
Other Revenue	0.01	0.04	0.01	0.02	-
Revenue	4.73	3.82	8.8	14.98	15.13
Revenue Growth (YoY)	23.83%	-56.58%	-41.24%	-0.94%	6.09%
Cost of Revenue	4.3	3.37	7.34	12.68	3.74
Gross Profit	0.43	0.45	1.46	2.3	11.39
Selling, General & Admin	0.35	0.27	0.96	1.43	0.69
Research & Development	-	-	-	-	0.37
Amortization of Goodwill & Intangibles	0.06	0.06	0.06	-	-
Other Operating Expenses	-	-	0.7	1.09	10.62
Operating Expenses	0.49	0.34	1.74	2.51	11.73
Operating Income	-0.06	0.11	-0.27	-0.21	-0.34
Interest Expense	-0.01	-0.03	-0.06	-0.07	-0.07
Other Non Operating Income (Expenses)	0.1	-	-	0.5	0.05
Pretax Income	0.03	0.08	-0.33	0.22	-0.36
Net Income	0.03	0.08	-0.33	0.22	-0.36
Net Income to Common	0.03	0.08	-0.33	0.22	-0.36
Net Income Growth	-59.83%	-	-	-	-
Free Cash Flow	0.29	0.07	-0.24	0.34	1.32
Gross Margin	9.09%	11.85%	16.63%	15.37%	75.30%
Operating Margin	-1.17%	2.95%	-3.08%	-1.40%	-2.23%
Profit Margin	0.68%	2.09%	-3.75%	1.49%	-2.35%
Free Cash Flow Margin	6.05%	1.88%	-2.71%	2.29%	8.75%
EBITDA	0.01	0.18	-0.26	-0.18	-0.33
EBITDA Margin	0.19%	4.80%	-2.99%	-1.23%	-2.17%
D&A For EBITDA	0.06	0.07	0.01	0.03	0.01
EBIT	-0.06	0.11	-0.27	-0.21	-0.34
EBIT Margin	-1.17%	2.95%	-3.08%	-1.40%	-2.23%
Revenue as Reported	4.73	3.82	8.8	14.98	15.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.